Five things that changed for clinics that prescribe, dispense or compound. Every item links to the agency that issued it.
Rule Watch, October 16, 2026: a telehealth visit does not replace the exam Read More »
Prescription length is set by the product, not the calendar. A compounded GLP-1 is limited by its beyond-use date. A manufactured testosterone vial is limited by its size and the controlled-substance rules.
Why a telehealth GLP-1 prescription runs 56 days and testosterone runs ten weeks Read More »
The exit is decided on the day you sign. Records follow the contract and state rules, patients follow their own choice, and the money follows whatever the agreement says about the last sweep.
Leaving a PC-MSO: who keeps the patients, the charts, the money and the prepaid packages Read More »
An unbranded RF microneedling pen from abroad may work fine. It still has no lawful path into a US treatment room, and no physician protocol can give it one.
Where patients are seen decides most of the policy list. A clinic, a rented room, a car and a laptop each carry a different exposure, and the medical director’s policy covers none of them.
Most wellness and weight-loss programs are cash-pay, and the answer patients get should be accurate the first time. What insurance does and doesn’t pay for, and the paperwork a self-pay patient is owed.
Toxin, filler and pharmacy accounts open on the physician’s credentials. What the director should hand over, what each document proves, and the address letter that can cost a license.
Supplier accounts with a medical director: NPI, DEA, license and the letter not to sign Read More »
The first round went after peptide vendors, a pharmacy and one med spa. The October filings add a weight-loss clinic and a professional practice. The research-use label did not keep anyone out.
Lilly’s retatrutide lawsuits now name clinics Read More »
An advisory committee said yes to six peptides. FDA staff said no to all seven. The law has not moved, and a reported stopgap is still only a report.
The FDA advisory vote on six peptides: what has to happen before a clinic can use them Read More »
Two phase 3 papers, two company toplines and a filing date. The data are strong. The drug is still not something you can lawfully prescribe.
Retatrutide trial results: what to tell patients who ask Read More »
Six peptides won a nonbinding vote in July. FDA’s own reviewers found controlled human data for none of them, and no human data at all for three.
The six peptides FDA’s advisers backed: what the human evidence shows Read More »
One amino acid decides whether retatrutide is a drug or a biologic. The answer will shape who can ever compound it, and it changes nothing about what you can offer today.
Is retatrutide a drug or a biologic? Why Lilly v. Kennedy matters to compounding Read More »
